DUBLIN–(BUSINESS WIRE)–The “TGF Beta Receptor Type 1 – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
TGF Beta Receptor Type 1 pipeline Target constitutes close to 17 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes.
This report outlays comprehensive information on the TGF Beta Receptor Type 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 9 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Furthermore, this report also reviews key players involved in TGF Beta Receptor Type 1 targeted therapeutics development with respective active and dormant or discontinued projects.
Report Scope
- The report provides a snapshot of the global therapeutic landscape for TGF Beta Receptor Type 1
- The report reviews TGF Beta Receptor Type 1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in TGF Beta Receptor Type 1 targeted therapeutics and enlists all their major and minor projects
- The report assesses TGF Beta Receptor Type 1 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to TGF Beta Receptor Type 1 targeted therapeutics
Key Topics Covered
- Introduction
- Report Coverage
- Overview
- Therapeutics Development
- Therapeutics Assessment
- Companies Involved in Therapeutics Development
- Drug Profiles
- Dormant Products
- Discontinued Products
- Product Development Milestones
Featured News & Press Releases
- Jul 19, 2019: MedPacto passes tech assessment, seeks KOSDAQ listing this year
- May 15, 2019: Eli Lilly presents update on phase Ib study of galunisertib at ASCO 2019
- Jan 23, 2019: Study Suggests new strategy to treat advanced Prostate Cancer
- Dec 21, 2018: MedPacto announce approval for the Vactosertib + Durvalumab Combination Trial Application
- Aug 31, 2017: Promising One-of-a-kind Clinical Trial Adds Immunotherapy to Colorectal Cancer Treatment Protocol
- May 18, 2016: Lilly to present data on TGF small-molecule kinase inhibitor galunisertib at ASCO
- May 14, 2013: Lilly Oncology To Release New Pipeline Data On TGF Beta Inhibitor LY2157299 At ASCO 2013
- Apr 10, 2013: Lilly Presents Data On TGF-beta Inhibitor LY2157299 At AACR Annual Meeting
- Jul 01, 2009: Graceway Pharmaceuticals Acquires Early-stage Dermatological Molecule Activin-Like Kinase 5 Inhibitor (ALK-5) From Pfizer
Companies Mentioned
- Allander Biotechnologies LLC
- Auxagen Inc
- Eli Lilly and Co
- FBM Therapeutics LLC
- GenFleet Therapeutics
- MedPacto Inc
- Pfizer Inc
- Shanghai Yingli Pharmaceutical Co Ltd
- SK Chemicals Co Ltd
- Synthis LLC
- Taisho Pharmaceutical Holdings Co Ltd
- TherapyX Inc
- Theravance Biopharma Inc
- TiumBio Co Ltd
- Yuhan Corp
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/j6y2lq
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900